



November 15, 2024

Splitrock Regulatory Solutions, LLC
Attention: James La Marta, Ph.D.
107 Decker Road
Boonton, NJ 07005

Re: GRAS Notice AGRN 70 – Serine Endopeptidase

Dear Dr. La Marta:

The Food and Drug Administration's (FDA) Center for Veterinary Medicine (CVM) refers to a generally recognized as safe (GRAS) notice, dated April 24, 2024, submitted on behalf of your client, AB Enzymes GmbH (the notifier). The subject of the notice is serine endopeptidase to be used as a processing aid to hydrolyze vegetable and animal proteins used as ingredients in food for all animal species. The submission informs us of the notifier's conclusion that the subject of the submission is GRAS through scientific procedures. The notice, as amended, was filed on June 27, 2024, and designated as animal GRAS notice number (AGRN) 70. In an October 15, 2024 email to you, CVM informed the notifier of questions regarding their conclusion. Specifically, CVM has questions related to the notifier's conclusion that utility does not impact safety as well as characterization of the genetic modifications to the host microorganism.

CVM is granting your request, dated November 13, 2024, to cease evaluation of AGRN 70. In accordance with 21 CFR 570.275(b)(2), the text of this letter responding to AGRN 70 is accessible to the public on our website for the Current Animal Food GRAS Notices Inventory at <https://www.fda.gov/animal-veterinary/generally-recognized-safe-gras-notificationprogram/current-animal-food-gras-notices-inventory>.

If you have any questions or comments, please contact Ms. Lauren LaPlace at 240-402-5350 or at lauren.laplace@fda.hhs.gov.

Sincerely,

/s/

David Edwards, Ph.D.
Director, Division of Animal Food Ingredients
Office of Surveillance and Compliance
Center for Veterinary Medicine